title: Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.
abstract: Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone. In cancer patients receiving high doses of the compound renal excretion may be associated with acute tubular necrosis. The question of how zoledronic acid is internalized by renal tubular cells has not been answered until now. In the current work, using a primary human tubular cell culture system, the pathway of cellular uptake of zoledronic acid (fluorescently/radiolabeled) and its cytotoxicity were investigated. Previous studies in our laboratory have shown that this primary cell culture model consistently mimics the physiological characteristics of molecular uptake/transport of the epithelium in vivo. Zoledronic acid was found to be taken up by tubular cells via fluid-phase-endocytosis (from apical and basolateral side) as evidenced by its co-localization with dextran. Cellular uptake and the resulting intracellular level was twice as high from the apical side compared to the basolateral side. Furthermore, the intracellular zoledronic acid level was found to be dependent on the administered concentration and not saturable. Cytotoxic effects however, were only seen at higher administration doses and/or after longer incubation times. Although zoledronic acid is taken up by tubular cells, no net tubular transport could be measured. It is concluded that fluid-phase-endocytosis of zoledronic acid and cellular accumulation at high doses may be responsible for the acute tubular necrosis observed in some cancer patients receiving high doses of the compound.
authors.affiliation: Laboratory of Pathophysiology, University of Antwerp, Antwerp, Belgium.
authors.forename: Anja
authors.initials: A
authors.lastname: Verhulst
authors.affiliation: Department of Chemistry, University of Southern California, Los Angeles, California, United States of America.
authors.forename: Shuting
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Chemistry, University of Southern California, Los Angeles, California, United States of America.
authors.forename: Charles E
authors.initials: CE
authors.lastname: McKenna
authors.affiliation: Laboratory of Pathophysiology, University of Antwerp, Antwerp, Belgium.
authors.forename: Patrick C
authors.initials: PC
authors.lastname: D'Haese
mesh_terms: D002478:Cells, Cultured; D004164:Diphosphonates / Q000009:adverse effects* / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004705:Endocytosis; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000493:pharmacokinetics*; D007684:Kidney Tubules / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid